Beloranib is a selective inhibitor of the receptor tyrosine kinase VEGFR2, functioning as an anti-angiogenic agent investigated for the treatment of solid tumors such as colorectal cancer and hepatocellular… Read more
Beloranib is a selective inhibitor of the receptor tyrosine kinase VEGFR2, functioning as an anti-angiogenic agent investigated for the treatment of solid tumors such as colorectal cancer and hepatocellular carcinoma. By blocking vascular endothelial growth factor signaling pathways, this compound inhibits tumor angiogenesis and growth. Laboratories require high-quality Beloranib reference standards, including the hemioxalate salt form, alongside associated impurities and metabolites to support rigorous analytical testing and quality control. Stable isotope labelled compounds for this drug are essential for precise bioanalytical method development and accurate quantification in complex matrices. These analytical tools allow researchers and pharmaceutical scientists to perform detailed impurity profiling and validate methods during stability studies, ensuring the integrity and consistency of pharmaceutical formulations throughout the development process.